Immune Evasion, TumorNCT07034339
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
An observational study of Immune Evasion, Tumor and Pancreas Cancer, run by First Affiliated Hospital of Zhejiang University at 1 site in China.
Trial summary
The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Immune Evasion, Tumor, Pancreas Cancer
- How many people
- 1,500 participants
- Where
- 1 siteChina
- Study dates
- 21 May 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants with pancreatic cancer, benign diseases, and healthy
Who may be able to join
- Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases
- Primary PDAC
- Patients with benign pancreatic tumors
- IPMN patients diagnosed by pathology/imaging
Who cannot join
- Having autoimmune diseases
- Accompanied by other malignant tumors
- History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years)
- Acute infection
- History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks
- Organ decompensation dysfunction
Show all 10Show fewer
- Immunodeficiency syndrome
- Hematological precancerous lesions
- Accept immunosuppressive therapy
- Diagnosed coagulation disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
the First Affliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003
Yangyang Wang, Doctor, 13957830918, 12418635@zju.edu.cn
About this study
The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, the investigators will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Additionally, the investigators will focus on specific immune cell subsets associated with pancreatic cancer evolution and treatment response, elucidating their roles and mechanisms in the occurrence, development, and drug resistance of pancreatic cancer. This project will establish a high-quality, standardized, and shareable pancreatic cancer immunity sample and data repository, refine the framework for multi-dimensional immunity data fusion and analysis, and create a time-space atlas of local and systemic immunity in pancreatic cancer. This will facilitate a deeper understanding of the dynamics of systemic and local immunity in early-stage pancreatic cancer and at various stages of its evolution, offering novel insights and approaches for the diagnosis and treatment of pancreatic cancer.
- Conditions
- Immune Evasion, Tumor, Pancreas Cancer
- Medical subject headings
- Neoplasms, Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Conventional treatment queue | Not described | |
| Dynamic follow-up queue | Not described | |
| Neoadjuvant therapy queue | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pancreatic tumor resection
Number of participants with pancreatic cancer
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2025
- Study start21 May 2025
- Primary completion1 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Immune Evasion, TumorStudies of the same condition, open and under way.
- More trials run by First Affiliated Hospital of Zhejiang UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qi Zhang, First Affiliated Hospital of Zhejiang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07034339
- Sponsor's protocol ID
- IDPEPDAC
- Status last verified
- Aug 2025
- First submitted
- 15 Jun 2025
- Last updated
- 6 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
- ClinicalTrials.gov ID
- NCT07034339
- Acronym / sponsor ID
- IDPEPDAC
- Conditions
- Immune Evasion, Tumor, Pancreas Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityUniversity, hospital or other
- Study start
- 21 May 2025 (actual)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 24 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, the investigators will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Additionally, the investigators will focus on specific immune cell subsets associated with pancreatic cancer evolution and treatment response, elucidating their roles and mechanisms in the occurrence, development, and drug resistance of pancreatic cancer. This project will establish a high-quality, standardized, and shareable pancreatic cancer immunity sample and data repository, refine the framework for multi-dimensional immunity data fusion and analysis, and create a time-space atlas of local and systemic immunity in pancreatic cancer. This will facilitate a deeper understanding of the dynamics of systemic and local immunity in early-stage pancreatic cancer and at various stages of its evolution, offering novel insights and approaches for the diagnosis and treatment of pancreatic cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Conventional treatment queue | – | – |
| Dynamic follow-up queue | – | – |
| Neoadjuvant therapy queue | – | – |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with pancreatic cancer, benign diseases, and healthy
Key inclusion criteria (4 listed)
- Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases
- Primary PDAC
- Patients with benign pancreatic tumors
- IPMN patients diagnosed by pathology/imaging
Key exclusion criteria (10 listed)
- Having autoimmune diseases
- Accompanied by other malignant tumors
- History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years)
- Acute infection
- History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pancreatic tumor resection
Time frame: 3 years
Number of participants with pancreatic cancer
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2025.
Related trials for Immune Evasion, Tumor
RecruitingObservational study
A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of Chemoresistance and Immune Evasion
Colorectal Cancer
RecruitingPhase 1
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
Non Small Cell Lung Cancer, Metastatic Lung Cancer
RecruitingObservational study
Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
Hepatocarcinoma
Not yet recruitingPhase 1/2
Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia
Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Immune Evasion, Tumor and Pancreas Cancer, run by First Affiliated Hospital of Zhejiang University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yangyang Wang (13957830918, 12418635@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pancreatic tumor resection (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2025.